Scar

Spring gives way to Canadian tattoo-removal stories, desires and fears

Retrieved on: 
火曜日, 5月 7, 2024
Scar, Pain, Ink, Tattoo, Growth, Skin, Life, Clothing, Mineral oil

TORONTO, May 07, 2024 (GLOBE NEWSWIRE) -- As the barometer rises, and spring begins to hit its stride, a nationwide survey of “tatted” Canadians tells a story of tattoo removal fears, for the 35 per cent of the country that have one or more tattoos.

Key Points: 
  • It is also a season when people begin to shed their layers of clothing and show off a little skin.
  • Half of tatted Canadians (51%) feel there is not enough information on tattoo removal.
  • One-in-three tatted Canadians (34%) feel that there are many health risks associated with laser tattoo removal.
  • One-in-four (25%) say the pain associated with laser tattoo removal steers them away from having it done.

aTyr Pharma to Present at Upcoming Investor Conferences

Retrieved on: 
月曜日, 5月 6, 2024
RBC, Human, Biology, Small RNA, Inflammation, Jefferies, Fibrosis, Scar

In addition to the presentations, company management will be available to participate in one-on-one meetings with investors who are registered attendees of the RBC and Jefferies conferences.

Key Points: 
  • In addition to the presentations, company management will be available to participate in one-on-one meetings with investors who are registered attendees of the RBC and Jefferies conferences.
  • A webcast of the RBC and Jefferies events will be available on the Investor’s section of the company’s website at www.atyrpharma.com .
  • Following the events, a replay of the RBC and Jefferies presentations will be available on the aTyr website for at least 90 days.
  • aTyr is a clinical stage biotechnology company leveraging evolutionary intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation.

Pulse Biosciences Announces First U.S. Procedure with the CellFX nsPFA Percutaneous Electrode System

Retrieved on: 
木曜日, 5月 9, 2024
Research, Medical Devices, FDA, Public Relations, Investor Relations, Communications, General Health, Pharmaceutical, Health, Science, Other Science, Collateral damage, Parathyroid gland, Safety, Thyroid nodule, Partnership, Lidocaine, U.S. FDA, Patient, Sarasota Memorial Hospital, Physician, Medicine, Scar

Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary CellFX® Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced the first procedure with the CellFX nsPFA Percutaneous Electrode System in the United States has been completed.

Key Points: 
  • Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary CellFX® Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced the first procedure with the CellFX nsPFA Percutaneous Electrode System in the United States has been completed.
  • I am looking forward to continuing my collaboration with Pulse Biosciences to further refine the procedure and offer this life-changing new technology to my patients and to help to train other experts in this exciting new procedure.”
    The CellFX nsPFA Percutaneous Electrode System consists of a percutaneous needle electrode for use with the Company’s proprietary CellFX nsPFA Console.
  • “Treating our first patient under our newly FDA-cleared nsPFA percutaneous system is a fundamental and opportune milestone for Pulse Biosciences,” said Mitch Levinson, Chief Strategy Officer of Pulse Biosciences.
  • Team Pulse Biosciences is deeply grateful to Dr. Tufano for his partnership over the past 3 years.

Top Atlanta Facial Plastic and Reconstructive Surgeon, Dr. Benjamin Stong, is Selected as a Faculty Member at the 2024 Global Aesthetics Conference

Retrieved on: 
火曜日, 4月 30, 2024
Rhinoplasty, University, General surgery, Suite, Heart, Nose, Conference, Patient, Physician, Multimedia, Emory University, Lip, Knowledge, Scar, Dentistry

ATLANTA, April 30, 2024 /PRNewswire-PRWeb/ -- Dr. Benjamin Stong, a renowned Atlanta plastic and reconstructive surgeon, is proud to announce that he has been selected as a faculty member at the prestigious 2024 Global Aesthetics Conference. The conference, taking place from November 7th to 10th, 2024, will be held in the vibrant city of Miami, Florida. This conference brings together some of the brightest minds in the field, and Dr. Stong, widely known for his groundbreaking techniques, will be sharing his expertise and insights with an esteemed audience of physicians and industry partners from around the world.

Key Points: 
  • ATLANTA, April 30, 2024 /PRNewswire-PRWeb/ -- Dr. Benjamin Stong, a renowned Atlanta plastic and reconstructive surgeon , is proud to announce that he has been selected as a faculty member at the prestigious 2024 Global Aesthetics Conference.
  • The conference, taking place from November 7th to 10th, 2024, will be held in the vibrant city of Miami, Florida.
  • Dr. Stong's state-of-the-art facility, Kalos Facial Plastic Surgery, is located in Buckhead which is right in the heart of Atlanta, Georgia.
  • Kalos Facial Plastic Surgery is located at 371 East Paces Ferry Rd, Suite 850 in Atlanta, Georgia.

The Next Level Deep Plane Face and Neck Lift: A Revolutionary Procedure for Natural and Long-Lasting Results

Retrieved on: 
木曜日, 4月 25, 2024
Scar, Neck, Multimedia, Patient, Skin, Face, Tissue, Medical device

In response to this, Dr. Ronald Demeo has introduced the Next Level Deep Plane Face and Neck Lift, a revolutionary technique that has been gaining popularity among patients.

Key Points: 
  • In response to this, Dr. Ronald Demeo has introduced the Next Level Deep Plane Face and Neck Lift, a revolutionary technique that has been gaining popularity among patients.
  • Dr. Ron's Next Level Deep Plane Face and Neck Lift has been praised by patients for its ability to provide a more youthful and rejuvenated appearance.
  • The Next Level Deep Plane Face and Neck Lift is just one of the many procedures offered by Dr. Ron to help patients look and feel their best.
  • For more information on the Next Level Deep Plane Face and Neck Lift and other cosmetic procedures offered by Dr. Ron, please visit [ https://meridiancosmetic.com/ ] or contact [phone number].

CHOP Researchers Discover Underlying Biology Behind Fontan-Associated Liver Disease

Retrieved on: 
水曜日, 4月 24, 2024
Online, Science Publishing Group, Fontan procedure, Patient, Cell, Hepatocyte, Liver disease, Inferior vena cava, Science Translational Medicine, Hope, NIH, Hospital, Blood, Tissue, Robert, CHOP, Agent handling, Heart, Wellness, MD, RNA, Medical laboratory, Doctor of Philosophy, SVRF, Activity, Survivor, Disease, Pathology, Ventricular septal defect, Fibrosis, Stasi, FC, Assistant, Biology, Children's Hospital of Philadelphia, Quality of life, Scar, Defense, Pharmaceutical industry

PHILADELPHIA, April 24, 2024 /PRNewswire/ -- As patients with congenital heart diseases live longer, researchers are attempting to understand some of the other complications they may face as they age. In a new study, a team from Children's Hospital of Philadelphia (CHOP) used state-of-the-art technologies to understand the underlying biology of Fontan-associated liver disease (FALD).

Key Points: 
  • In a new study, a team from Children's Hospital of Philadelphia (CHOP) used state-of-the-art technologies to understand the underlying biology of Fontan-associated liver disease (FALD).
  • The Fontan operation is the current standard of care for single-ventricle congenital heart disease.
  • As more patients undergo the Fontan surgery for single-ventricle congenital heart disease, FALD has become a more recognized problem.
  • Little information exists on FALD, yet it is distinct from other forms of liver disease, which is why researchers at CHOP wanted to understand the basic biology that could lead to better treatment options and improve these patients' quality of life.

NJ Lawyer Howard Lesnik Settles Seriously Injured Motorcyclist Claim from Accident with a Dump Truck for $625,000

Retrieved on: 
火曜日, 4月 23, 2024
Neck, Crash, Injury, New Jersey Superior Court, Spine, Insurance, Human, Scar, Face, Ridesharing

With no time for the motorcyclist to react, the large truck crashed into his motorcycle , sending him flying onto the roadway.

Key Points: 
  • With no time for the motorcyclist to react, the large truck crashed into his motorcycle , sending him flying onto the roadway.
  • His attorney, Howard Lesnik of Mountainside NJ, filed a lawsuit in New Jersey Superior Court.
  • Prior to trial, the defense attorneys for the dump truck requested that this case be arbitrated by a professional mediator.
  • However, before arbitration, Mr. Lesnik was able to settle a claim against the dump truck and its driver for $625,000.00.

Dr. Ron: The Pioneer of Next Level Deep Plane Face and Neck Lift

Retrieved on: 
金曜日, 4月 19, 2024
Scar, Patient, Face, Publication, Dentistry

The Next Level Deep Plane Face and Neck Lift is a revolutionary procedure that has been gaining popularity among patients seeking a more natural and long-lasting result.

Key Points: 
  • The Next Level Deep Plane Face and Neck Lift is a revolutionary procedure that has been gaining popularity among patients seeking a more natural and long-lasting result.
  • The Next Level Deep Plane Face and Neck Lift is just one of the many procedures offered by Dr. Ron at his state-of-the-art clinic.
  • Dr. Ron's Next Level Deep Plane Face and Neck Lift is a game-changer in the world of cosmetic surgery, and it is no surprise that it has been making waves in the industry.
  • For those seeking a more natural and long-lasting result, Dr. Ron's Next Level Deep Plane Face and Neck Lift is definitely worth considering.

Orphan designation: Tranilast Prevention of scarring post glaucoma filtration surgery, 27/07/2010 Positive

Retrieved on: 
木曜日, 4月 18, 2024
Eurostat, Diagnosis, Civil service commission, Optic nerve, Brain, Pressure, Cell, Disease, Risk, Patient, Committee, Knowledge, Regulation, Cancer, EMA, IRIS, Scar, Eye, Wound healing, European, Allergic conjunctivitis, COMP, Collagen, Skin, European Commission, Safety, Glaucoma, Sclera, Pharmaceutical industry

Orphan designation: Tranilast Prevention of scarring post glaucoma filtration surgery, 27/07/2010 Positive

Key Points: 


Orphan designation: Tranilast Prevention of scarring post glaucoma filtration surgery, 27/07/2010 Positive

aTyr Pharma to Participate in April Investor Conferences

Retrieved on: 
月曜日, 4月 1, 2024
Human, Inflammation, Biology, SAN, Scar, ATyr Pharma, Fibrosis, Small RNA, Evercore, Pharmaceutical industry

SAN DIEGO, April 01, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the company will participate in two upcoming investor conferences scheduled to take place in April 2024.

Key Points: 
  • SAN DIEGO, April 01, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the company will participate in two upcoming investor conferences scheduled to take place in April 2024.
  • Details of the conferences appear below:
    For more information on how to register, please contact your Evercore ISI or Piper Sandler representative.
  • aTyr is a clinical stage biotechnology company leveraging evolutionary intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation.
  • tRNA synthetases are ancient, essential proteins that have evolved novel domains that regulate diverse pathways extracellularly in humans.